Please Update your browser

Your browser is out of date, and may not be compatible with our website. A list of the most popular web browsers can be found below.
Just click on the icons to get to the download page.

Jakarta Post

COVID-19 drug buyout threatens developing nations

  • Dono Widiatmoko

    Derby, United Kingdom

Derby, United Kingdom   /   Thu, July 16 2020   /  01:00 am
In this file photo taken on April 30, 2020 Gilead Sciences headquarters sign is seen in Foster City, California. - The experimental drug Remdesivir has been authorized by US regulators for emergency use against COVID-19, President Donald Trump announced on May 1, 2020.(AFP/Josh Edelson)

United States President Donald Trump has announced an extraordinary deal to ensure that Americans have access to the first authorized drug treatment for COVID-19: remdesivir, the first drug approved by the US Food and Drug Administration to treat COVID-19 that is made by American pharmaceuticals company Gilead Sciences. The deal was announced as it became clear that the US epidemic was spiraling out of control. At the same time, Anthony Fauci, the country’s leading public health expert who is leading the nation’s COVID-19 response, testified before the Senate that the US was sliding backward in its mitigation efforts. Gilead holds the patent for the drug, which was invented for Ebola but failed in human trials against that disease, which means that no other company can make it. The first 140,000 doses that were supplied for drug trials around the world have been used up...